Johnson & Johnson (JNJ-N) Stock Predictions - Stockchase
WATCH LIST
397
Johnson & Johnson (JNJ-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Johnson & Johnson Johnson & Johnson
JNJ-N

144 397
biotechnology/pharmaceutical

Johnson & Johnson (JNJ-N) SAVE

139.05

0.45 (0.32%)

Oct, 20, 2018, 12:00 am

OPINIONS

About Johnson & Johnson (JNJ-N)

Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886. More at Wikipedia

What the experts are saying about JNJ-N



  • All
  • Filtered
Signal Opinion Expert
BUY
Johnson & Johnson(JNJ-N) 

October 11, 2018

Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run. 

biotechnology/pharmaceutical

Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run. 

biotechnology/pharmaceutical
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$133.840
Owned Owned
Yes

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

October 10, 2018

(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive
environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield.

biotechnology/pharmaceutical

(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive
environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield.

biotechnology/pharmaceutical
Adam Thomas

Vice Presi, Qwest Fund Managemen...

Price Price
$137.730
Owned Owned
Yes

BUY
Johnson & Johnson(JNJ-N) 

August 30, 2018

He loves it.  The judgment against them is not significant.  He has a model price of $160.81, a 20% upside.  It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.

biotechnology/pharmaceutical

He loves it.  The judgment against them is not significant.  He has a model price of $160.81, a 20% upside.  It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$134.950
Owned Owned
Unknown

COMMENT
Johnson & Johnson(JNJ-N) 

August 27, 2018

Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J.

biotechnology/pharmaceutical

Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J.

biotechnology/pharmaceutical
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$134.920
Owned Owned
Unknown

TOP PICK
Johnson & Johnson(JNJ-N) 

July 10, 2018

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

biotechnology/pharmaceutical

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

biotechnology/pharmaceutical
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$127.380
Owned Owned
Yes

BUY

It is a very well run company.  Pharma, medical supply and personal goods businesses.  The pharma business is doing well.  They have a number of drugs.  Brands are not as valued by millennials as by their predecessors.  This is the struggle that JNJ-N is having.  They have a strong balance sheet and a nice dividend.

biotechnology/pharmaceutical

It is a very well run company.  Pharma, medical supply and personal goods businesses.  The pharma business is doing well.  They have a number of drugs.  Brands are not as valued by millennials as by their predecessors.  This is the struggle that JNJ-N is having.  They have a strong balance sheet and a nice dividend.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment ...

Price Price
$123.330
Owned Owned
Unknown

PAST TOP PICK

(Past Top Pick on May 16, 2017, Down 1.5%)  Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year.  Yield under 3%.

biotechnology/pharmaceutical

(Past Top Pick on May 16, 2017, Down 1.5%)  Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year.  Yield under 3%.

biotechnology/pharmaceutical
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$122.610
Owned Owned
Yes

BUY
Johnson & Johnson(JNJ-N) 

April 27, 2018

This is one of the “bluest” blue chip with a AAA credit rating.  Consumer staples companies have had a tough time this year.  It is a fabulous company and has several levers it could pull to unlock value.  It is a good defensive investment with a good yield. 

biotechnology/pharmaceutical

This is one of the “bluest” blue chip with a AAA credit rating.  Consumer staples companies have had a tough time this year.  It is a fabulous company and has several levers it could pull to unlock value.  It is a good defensive investment with a good yield. 

biotechnology/pharmaceutical
David Dietze

Founder, P, Point View Wealth Ma...

Price Price
$128.270
Owned Owned
Yes

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

April 16, 2018

(A Past Top Pick on May 16, 2017, Up 6%) Expects tomorrow's Q1 report to be good. They're seeing good growth in their pharmaceutical division. They invest in their pipeline, so there's organic growth; They also make strategic acquisitions, like a Swiss biotech last year that focuses on heart diseases. In the pharma side, their investments are starting to pay off and offsetting some of their drugs going generic. A defensive play with strong financials.

biotechnology/pharmaceutical

(A Past Top Pick on May 16, 2017, Up 6%) Expects tomorrow's Q1 report to be good. They're seeing good growth in their pharmaceutical division. They invest in their pipeline, so there's organic growth; They also make strategic acquisitions, like a Swiss biotech last year that focuses on heart diseases. In the pharma side, their investments are starting to pay off and offsetting some of their drugs going generic. A defensive play with strong financials.

biotechnology/pharmaceutical
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$131.760
Owned Owned
Yes

BUY
Johnson & Johnson(JNJ-N) 

March 21, 2018

Long-term, this is the one to own. A dominant player in medtech and pharma. 10% of their revenue has been from one drug. Competition is weak. A well-run, large company. Valuations are okay. An anchor in his portfolio. Their diversified
portolio of drugs can withstand the failure of one.

biotechnology/pharmaceutical

Long-term, this is the one to own. A dominant player in medtech and pharma. 10% of their revenue has been from one drug. Competition is weak. A well-run, large company. Valuations are okay. An anchor in his portfolio. Their diversified
portolio of drugs can withstand the failure of one.

biotechnology/pharmaceutical
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$131.190
Owned Owned
Yes

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

February 13, 2018

(A Top Pick February 17, 2017. Up 11.49%). Still likes it and added to her portfolio as it pulled back last week. Their pharma business is doing quite well. This is their highest-margin business. They invest about 13% of revenues into R&D, which supports a strong pipeline. They will use some of their strong cash flow to pay down debt. Their dividend, 2%, has grown every year for 55 years.

biotechnology/pharmaceutical

(A Top Pick February 17, 2017. Up 11.49%). Still likes it and added to her portfolio as it pulled back last week. Their pharma business is doing quite well. This is their highest-margin business. They invest about 13% of revenues into R&D, which supports a strong pipeline. They will use some of their strong cash flow to pay down debt. Their dividend, 2%, has grown every year for 55 years.

biotechnology/pharmaceutical
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$129.960
Owned Owned
Yes

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

February 7, 2018

(A Top Pick April 20/17, Up 10%) Recent pullback partially due to scare about their talcum powder. JNJ is the biggest, most diversified healthcare company in the world. Deserves to trade at a premium—16 times next year earnings. It should be worth more. Divident solid. Great pipeline in pharmaceuticals and medical devices. Healthcare is his biggest overweight in the U.S.

biotechnology/pharmaceutical

(A Top Pick April 20/17, Up 10%) Recent pullback partially due to scare about their talcum powder. JNJ is the biggest, most diversified healthcare company in the world. Deserves to trade at a premium—16 times next year earnings. It should be worth more. Divident solid. Great pipeline in pharmaceuticals and medical devices. Healthcare is his biggest overweight in the U.S.

biotechnology/pharmaceutical
Lorne Zeiler

Portfolio , TriDelta Financial...

Price Price
$131.420
Owned Owned
Unknown

WEAK BUY
Johnson & Johnson(JNJ-N) 

February 6, 2018

Has dropped, along with everything else. You have to consider whether it is cheap at this level. If you look beyond the past few days, you will see that at the beginning of 2017, it was trading at about $100 per share. Now it is over $128, so today’s price is significantly increased over a short time. The business trades at a low multiple at this level (15 to 16 times earnings), near “cheap” levels. JNJ is made up of three businesses: pharma, consumer products and medical devices. The company might be more interesting if it split these into separate businesses. He doesn’t think investors will go wrong by holding this company as is, but this is not a pound-the-table opportunity at this price.

biotechnology/pharmaceutical

Has dropped, along with everything else. You have to consider whether it is cheap at this level. If you look beyond the past few days, you will see that at the beginning of 2017, it was trading at about $100 per share. Now it is over $128, so today’s price is significantly increased over a short time. The business trades at a low multiple at this level (15 to 16 times earnings), near “cheap” levels. JNJ is made up of three businesses: pharma, consumer products and medical devices. The company might be more interesting if it split these into separate businesses. He doesn’t think investors will go wrong by holding this company as is, but this is not a pound-the-table opportunity at this price.

biotechnology/pharmaceutical
Kash Pashootan

Sr. VP & P, First Avenue Advisor...

Price Price
$131.830
Owned Owned
No

BUY
Johnson & Johnson(JNJ-N) 

February 1, 2018

They owned it and sold it moving the money to another pharmaceutical that was offering better value. Good company. 2.4% dividend yield. Trades at 17 earnings. Had a higher multiple not long ago. Unique in the sense that has three different businesses: pharma, consumer products and medical devices. Those three together has made it very profitable and diversified. Increase its dividend for the last 15 years in a row. They make good small acquisitions. If the market pull back, it is a protective stock as it won’t collapse. Very stable business.  

biotechnology/pharmaceutical

They owned it and sold it moving the money to another pharmaceutical that was offering better value. Good company. 2.4% dividend yield. Trades at 17 earnings. Had a higher multiple not long ago. Unique in the sense that has three different businesses: pharma, consumer products and medical devices. Those three together has made it very profitable and diversified. Increase its dividend for the last 15 years in a row. They make good small acquisitions. If the market pull back, it is a protective stock as it won’t collapse. Very stable business.  

biotechnology/pharmaceutical
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$140.020
Owned Owned
No

BUY
Johnson & Johnson(JNJ-N) 

January 9, 2018

She likes this, because their pharmacy division is doing very well in terms of product pipeline development and new products they’ve launched in the last 2 years. Their Pharma division is the most profitable and very beneficial to the bottom line. This will be benefiting from the US tax cuts. An attractive yield of 2.4%.

biotechnology/pharmaceutical

She likes this, because their pharmacy division is doing very well in terms of product pipeline development and new products they’ve launched in the last 2 years. Their Pharma division is the most profitable and very beneficial to the bottom line. This will be benefiting from the US tax cuts. An attractive yield of 2.4%.

biotechnology/pharmaceutical
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$144.140
Owned Owned
Yes

Showing 1 to 15 of 397 entries

No Comments.


You must be logged in to comment.

Successfully Saved Company
Successfully Saved Company